COST-EFFECTIVENESS ANALYSIS OF CRIZOTINIB VERSUS CHEMOTERAPY FOR FIRST LINE TREATMENT OF NONSMALL CELL LUNG CANCER ALK plus , FROM THE BRAZILIAN PUBLIC HEALTHCARE SYSTEM PERSPECTIVE

被引：0
|
作者：
Ferreira, P. [1 ]
Senna, T. [1 ]
Sebastiao, M. [1 ]
Alexandre, R. F. [1 ]
Almeida, P. [1 ]
机构：
[1] Pfizer, Sao Paulo, SP, Brazil
来源：
VALUE IN HEALTH | 2023年 / 26卷 / 06期
关键词：
D O I：
暂无
中图分类号：
F [经济];
学科分类号：
02 ;
摘要：
EE52
引用
收藏
页码：S68 / S69
页数：2
相关论文
共 50 条
  • [1] COST-EFFECTIVENESS ANALYSIS OF ALECTINIB VERSUS CRIZOTINIB IN FIRST LINE ALK-POSITIVE ADVANCED NON-SMALL CELL LUNG CANCER IN THE BRAZILIAN PRIVATE HEALTHCARE SYSTEM PERSPECTIVE
    Stefani, S. D.
    Santos, M.
    Kashiura, D.
    Leme-Souza, R.
    Fahham, L.
    [J]. VALUE IN HEALTH, 2019, 22 : S478 - S479
  • [2] COST-EFFECTIVENESS OF NIVOLUMAB VERSUS DACARBAZINE IN FIRST-LINE TREATMENT OF ADVANCED MELANOMA FROM BRAZILIAN PUBLIC HEALTHCARE SYSTEM PERSPECTIVE
    Casagrande Oliveira, A. P.
    Hamza, S.
    Koloszuk, A.
    Marinheiro, P.
    Bernardino, G.
    [J]. VALUE IN HEALTH, 2020, 23 : S41 - S41
  • [3] Cost-effectiveness of alectinib compared to crizotinib for the treatment of first-line ALK plus advanced non-small-cell lung cancer in France
    Sivignon, Marine
    Monnier, Remi
    Tehard, Bertrand
    Roze, Stephane
    [J]. PLOS ONE, 2020, 15 (01):
  • [4] COST-EFFECTIVENESS OF SEQUENTIAL TREATMENT CONTAINING CRIZOTINIB FOR NON SMALL CELL LUNG CANCER (ALK plus ) PATIENTS
    Sabater Cabrera, E.
    Puente, J.
    Oyaguez, I
    Garcia-Campelo, R.
    Reguart, N.
    Rodriguez, D.
    Cobo, M.
    Soto, J.
    Moran, M.
    [J]. VALUE IN HEALTH, 2017, 20 (09) : A443 - A444
  • [5] COST-EFFECTIVENESS ANALYSIS OF CRIZOTINIB IN METASTATIC ALK plus NON-SMALL CELL LUNG CANCER (NSCLC)
    Montero, Alberto J.
    Lopes, Gilberto
    [J]. JOURNAL OF THORACIC ONCOLOGY, 2013, 8 : S1211 - S1212
  • [6] COST-EFFECTIVENESS ANALYSIS OF TOFACITINIB IN THE TREATMENT OF ULCERATIVE COLITIS IN THE PERSPECTIVE OF BRAZILIAN PUBLIC HEALTHCARE SYSTEM
    Holanda, P.
    Salgado De Santana, C.
    Senna, T.
    Carmo, L.
    Alexandre, R. F.
    [J]. VALUE IN HEALTH, 2021, 24 : S96 - S96
  • [7] First-Line Lorlatinib Versus Crizotinib for Advanced Anaplastic Lymphoma Kinase-Positive (ALK plus ) NonSmall Cell Lung Cancer
    Shaw, A.
    Bauer, T.
    Takahashi, T.
    Balk, C.
    Goto, Y.
    Polli, A.
    Carpentieri, M.
    Martini, J.
    Solomon, B.
    [J]. JOURNAL OF THORACIC ONCOLOGY, 2018, 13 (10) : S584 - S584
  • [8] Cost-effectiveness of ALK testing and first-line crizotinib therapy for non-small-cell lung cancer in China
    Lu, Shun
    Yu, Yongfeng
    Fu, Shijun
    Ren, Hongye
    [J]. PLOS ONE, 2018, 13 (10):
  • [9] COST-EFFECTIVENESS OF CRIZOTINIB FOR FIRST-LINE TREATMENT IN NON-SMALL CELL LUNG CANCER IN ECUADOR
    Salcedo, E.
    Freire, V
    Cabezas, M.
    Albert, A.
    [J]. VALUE IN HEALTH, 2018, 21 : S32 - S32
  • [10] First-line atezolizumab plus chemotherapy in treatment of extensive small cell lung cancer: a cost-effectiveness analysis from China
    Li Ling-Yu
    Wang Hong
    Chen Xiao
    Li Wen-Qian
    Cui Jiu-Wei
    [J]. 中华医学杂志(英文版), 2019, 132 (23) : 2790 - 2794
12345